Status: Finalised
First registered on:
19/02/2021
Last updated on:
09/01/2023
1. Study identification
EU PAS Register NumberEUPAS39361
Official titleACCESS template protocol for safety of COVID-19 vaccines
Study title acronymACCESS
Study typeObservational study
Brief description of the studyThis listing includes the four different safety protocol templates to monitor COVID-19 vaccine safety. These protocols were prepared on request of EMA and have been reviewed by EMA and stakeholders. Protocols require finalization by the final users and are not conducted as such.
This registration includes the following protocols:
1. Cohort event monitoring to assess safety of COVID-19 vaccines using patient reported events, a protocol template from the ACCESS project
2. Rapid assessment of COVID-19 vaccines safety concerns through electronic health records: a protocol template from the ACCESS project
3. Safety evaluation of COVID-19 vaccines through electronic health records: a protocol template from the ACCESS project
4. Safety Protocol for Hospital Case–Based Monitoring of Specific Adverse Events Following COVID-19 Vaccines: A Protocol Template from the ACCESS project
Section 19 includes the template protocols. Word documents can be retrieved from study authors or PI.
Section 19 includes the final ACCESS report with feasibility assessment
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsUMCU
Department/Research groupJulius Center
Organisation/affiliationUniversity Medical Center Utrecht
Details of (Primary) lead investigator
Title Professor
Last name Sturkenboom
First name Miriam
Is this study being carried out with the collaboration of a research network?
Yes
EU PE&PV research network
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?20
Countries in which this study is being conducted
International study
Belgium
Denmark
France
Italy
Netherlands
Norway
Spain
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed21/05/202021/05/2020
Start date of data collection21/05/202021/05/2020
Start date of data analysis
Date of interim report, if expected
Date of final study report15/12/202030/06/2021
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding scheme
OtherEMA100
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Sturkenboom
First name Miriam
Address line 1Heidelberglaan 100
Address line 2
Address line 3
CityUtrecht
Postcode
CountryNetherlands
Phone number (incl. country code)31657831983
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Sturkenboom
First name Miriam
Address line 1Heidelberglaan 100
Address line 2
Address line 3
CityUtrecht
Postcode
CountryNetherlands
Phone number (incl. country code)31657831983
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Not applicable (disease/epidemiology study)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Preterm newborns
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Other population
Renal impaired
Hepatic impaired
Immunocompromised
Pregnant women
9. Number of subjects
Estimated total number of subjects1000000
Additional information
Number is not yet decided, will depend on the study implementation. This EU PAS registration includes protocol templates only.
10. Source of data
Is this study being carried out with an established data source?No
Sources of data
Choice of data sources depends on the protocol template and the study implementation
11. Scope of the study
What is the scope of the study?
Risk assessment
Primary scope : Risk assessment
12. Main objective(s)
What is the main objective of the study?
Assess the safety of COVID-19 vaccines
Are there primary outcomes?Yes
All AESI
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Depends on the study implementation
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Several years, depends on the study implementation
15. Data analysis plan
Please provide a brief summary of the analysis method
Depends on the study protocol template and study implementation
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documents
DescriptionDocumentLatest version
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
